- IsoPlexis offers resources to ensure every lab’s experiments using the functional proteomics platform goes smoothly. IsoU provides researchers with the tools to get started with training modules which demonstrate how to prepare samples, execute runs, analyze data, and apply results obtained from the Single-Cell Intracellular Proteome solution and all other IsoPlexis solutions.
- IsoPlexis’ webinar and poster on the p53 pathway explains the effects of p53 on cancer cell changes, and how the Single-Cell Intracellular Proteome solution can be used to characterize and resolve such pathways. These resources give insight into how researchers can apply IsoPlexis’ technology to make critical discoveries in oncology.
IsoPlexis’ Award-Winning Intracellular Signaling Omics Application Accelerates Proteomic Insights
IsoPlexis offers free resources to help researchers make the most of their experiments. From eBooks showcasing exciting data using our technology to on-demand webinars highlighting case studies from leading institutions, we want to remind our users of the tools that are at their fingertips. The IsoUniversity section of our website provides detailed protocols for our many solutions and applications and highlights the various uses and features of the IsoPlexis platform to ensure that you get the most out of our unique technology. For each solution, IsoUniversity offers training modules for preparing samples, executing the run, analyzing data, and applying results to identify biomarkers and predict outcome. Here, we’d like to highlight a few resources surrounding our new, award-winning Single-Cell Intracellular Proteome solution.
Webinar Highlights Critical Roles of p53 and IsoPlexis’ Single-Cell Intracellular Proteome Solution
IsoPlexis’ webinar with Dr. Arnold Levine, Professor of Systems Biology at the Institute for Advanced Study, explains the p53 pathway, its impact on cancer research, and the use of IsoPlexis’ solutions to overcome cancer cell resistance. The p53 gene, which was discovered by Dr. Levine and his colleagues at Princeton in 1979, regulates many important cell processes, including the cell cycle, DNA repair, apoptosis, senescence, and angiogenesis. A mutation of p53 is found in more than half of all human cancers, making this tumor protein a critical focus for the development of cancer therapies.1 Mutations to p53 can prevent it from regulating many aspects of the immune system, leading to cancer cell proliferation, tumorigenesis, tumor growth, and metastasis.
In the second portion of this webinar, a study published in Cancer Cell by Wei, et al. that analyzed single cells including p53 tumor pathway biomarkers of glioblastoma multiforme (GBM) patients is discussed. The researchers characterized the intracellular proteome of control, treatment-responsive, and treatment-resistant GBM cells after treatment with a targeted inhibitor. IsoPlexis’ Single-Cell Intracellular Proteome solution revealed heterogenous signaling networks which were able to adapt rapidly to drive resistance.2 IsoPlexis assessed the protein levels and protein-to-protein correlations to find that treatment with the targeted inhibitor diminished levels of most proteins and protein correlations. IsoPlexis’ technology accurately predicted the anti-cancer effect of seven monotherapies, and ultimately found that combination therapies targeting one protein from each mode were the most effective at suppressing tumor growth. By revealing unique functional trajectories to drug tolerance in small subsets of cells, IsoPlexis’ intracellular signaling omics furthered understanding of the mechanisms driving resistant GBM cell states, and how they could be treated.
To further elucidate the critical roles of p53, its relationship to cancer development, and how IsoPlexis’ intracellular signaling omics identifies and resolves resistance pathways, our downloadable p53 poster includes visualizations of the effects of p53 mutation and explains the possibilities and limitations of research on the restoration of p53 to fight cancer. In addition, the p53 poster explains the role of superhero and supervillain cells, the polyfunctional cells which drive immune response, and their relationship to signaling pathways such as p53 and cancer.
IsoPlexis’ unique applications, including intracellular signaling omics, are now accessible to virtually every lab with the release of two new proteomics hubs that make the platform more scalable and flexible than ever. The IsoSpark provides the same gold standard highly multiplexed proteomics as the IsoLight system, with a reduced footprint, price point, and chip capacity, making it perfect for smaller labs or labs running low throughput studies. The IsoSpark Duo matches the IsoLight’s 8-chip capacity and adds the ability for researchers to run multiple different cell types simultaneously for complete functional immune landscaping. These end-to-end automated systems greatly accelerate therapeutic timelines, returning data insights and visualizations in hours or days.
To learn more about this unique application and its impact on personalized medicine, download our Single-Cell Intracellular Proteome eBook or visit IsoPlexis University to access detailed protocols and training modules for this solution and our other applications. This award-winning intracellular proteome solution was officially launched on December 2nd in a virtual event—if you missed it, you can view it here.
- Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer 188, 2020.
- Wei W, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell, 29: 563-573, 2016.